Evidence map›Paper›PMID 39513295›Full record

ArticleJournal of global health2024

Low antiviral uptake of nirmatrelvir/ritonavir and molnupiravir in adult patients with COVID-19 in Taiwan in 2022.

Fu-Der Wang, Phung-Anh Nguyen, David Lee, Bulent Taysi, Florence Lefebvre d'Hellencourt, Julia Spinardi, Phan Thanh Phuc, Whitney Burton, Yu-Hui Chang, Nguyen Thi Kim Hien and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of global health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Underutilization of nirmatrelvir/ritonavir in eligible COVID-19 patients.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Fu-Der WangDivision of Infectious Diseases, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
Phung-Anh NguyenGraduate Institute of Data Science, College of Management, Taipei Medical University, Taipei, Taiwan.
David LeePfizer, Taipei, Taiwan.
Bulent TaysiPfizer, Singapore.
Florence Lefebvre d'HellencourtPfizer, New York, USA.
Julia SpinardiPfizer, New York, USA.
Phan Thanh PhucInternational PhD Program in Biotech and Healthcare Management, College of Management, Taipei Medical University, Taipei, Taiwan.
Whitney BurtonInternational PhD Program in Biotech and Healthcare Management, College of Management, Taipei Medical University, Taipei, Taiwan.
Yu-Hui ChangSchool of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Nguyen Thi Kim HienMaster Program in Global Health and Development, College of Public Health, Taipei Medical University, Taipei City, Taiwan.
Shiue-Ming LinResearch Center of Health Care Industry Data Science, College of Management, Taipei Medical University, Taipei, Taiwan.
Yang ChiehResearch Center of Health Care Industry Data Science, College of Management, Taipei Medical University, Taipei, Taiwan.
Moe H KyawPfizer, New York, USA.
Jason C HsuClinical Data Center, Office of Data Science, Taipei Medical University, Taipei, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Antivirals are effective in reducing hospitalisation and death in mild-to-moderate coronavirus 2019 (COVID-19) patients. We estimated the antiviral uptake of nirmatrelvir/ritonavir and molnupiravir in adult patients with a syndrome coronavirus 2 (SARS-CoV-2) infection during the Emergency Use Authorization (EUA) period in Taiwan. Methods: A retrospective cohort study was conducted in Taiwan between January 2022 and December 2022. Patients aged ≥18 years with a SARS-CoV-2 infection were included from the Taipei Medical University Clinical Research Database (TMUCRD) and stratified in three risk groups according to World Health Organization criteria. Results: In total, 96 398 COVID-19 patients (mean age 46.7 ± 17.7 years, 45.8% male) were included. Of these patients 69.8% were classified as low risk, 29.8% as moderate risk, and 0.4% as high risk for progression to severe COVID-19. Nirmatrelvir/ritonavir was prescribed in 5.1% of the COVID-19 patients (low risk = 1.0%, moderate risk = 14.3%, high risk = 17.6%). Molnupiravir was prescribed in 1.9% of the COVID-19 patients (low risk = 0.1%, moderate risk = 5.8%, high risk = 6.9%). Conclusions: Nirmatrelvir/ritonavir and molnupiravir were poorly used in the treatment of adult COVID-19 patients in Taiwan during the pandemic in 2022, especially in moderate-to-high risk groups for progression to severe COVID-19.

Indexed as

Antiviral AgentsCOVID-19COVID-19 Drug TreatmentHydroxylaminesRitonavirSARS-CoV-2AdultAgedCytidineFemaleHumansLactamsLeucineMaleMiddle AgedNitrilesAntiviral AgentsCytidineHydroxylaminesLactamsLeucinemolnupiravirnirmatrelvirNitrilesOrganometallic CompoundsProlinePyrrolidinesRitonavirSulfonamides

Identifiers

PMID39513295
PMCPMC11544516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.